Skip to content
Open access

Affinity and costimulatory architecture-associated toxicity in mesothelin-targeted TCR-mimetic CAR-T cells

Sep 2026 · Frontiers in Immunology · Vol 17 · 0 citations · 43 references
Medicine

TL;DR

Modifying either the affinity-related properties or the 80BB-based architecture preserved efficacy while reducing toxicity, providing potential design considerations for affinity selection and co-stimulator design in the mesothelin-targeted TCR-mimetic CAR-T platform.

Abstract

Introduction TCR-mimetic CAR-T combines antibody-based targeting with physiological TCR signaling, yet suboptimal co-stimulation and safety risks remain key barriers for solid tumor therapy. The prevailing assumption that stronger co-stimulation yields superior efficacy has not been systematically tested in TCR-mimetic CAR-T architectures. Methods We developed a Mesothelin-targeted scFv-CD3ϵ TCR-mimetic CAR-T platform and systematically compared co-stimulatory modules—4-1BB, BRM-truncated 4-1BBΔBRM, and the 80BB chimera—alongside CD3ζ overexpression. To define the requirements for toxicity, we generated a series of control constructs and compared SS1 versus MOR-based scFvs targeting the same antigen, which differ in their binding properties including affinity. Results The optimized SS1-ϵζ-80BB TCR-mimetic CAR-T exhibited potent anti-tumor activity but unexpectedly induced dose-dependent lethal toxicity. Systematic controls identified the intact 80BB chimera as the construct associated with lethality. Deleting the 4-1BB intracellular domain, rerouting the 4-1BB intracellular domain to an antigen-dependent format, or replacing SS1 with MOR each abrogated toxicity while preserving anti-tumor efficacy. The SS1-ϵζ-80BB architecture was associated with excessive T-cell expansion and multi-organ infiltration while the MOR-ϵζ-80BB architecture was moderate. Discussion These observations suggest that the mode of co-stimulatory configuration, rather than its mere presence, influences safety outcomes in TCR-mimetic CAR-T cells. Modifying either the affinity-related properties or the 80BB-based architecture preserved efficacy while reducing toxicity, providing potential design considerations for affinity selection and co-stimulator design in the mesothelin-targeted TCR-mimetic CAR-T platform.

Read PDF

Similar papers

Open access Sep 2026

Structure-function profiling identifies determinants of TCR-T cell therapeutic efficacy

A mechanistic basis and a conceptual framework for the selection and optimization of TCRs for adoptive immunotherapy are provided for the selection and optimization of TCRs for adoptive immunotherapy.

Leire Oyon-Olea, Enric Vercher, M. G. Dichiara-Rodríguez et al. · 0 citations
Open access Sep 2026

T cell receptors equipped with ICOS provide T cells with durable anti-tumor response

A novel and uniformly applicable TCR:ICOS format that supports fitter T cell products for adoptive cell therapy and identifies a single amino acid change in the cytosolic tail which enabled functional surface expression without proneness to TCR mispairing nor competition for CD3.

Alexandre Marraffa, C. Berrevoets, Margherita Mosiello et al. · 0 citations
Open access Sep 2026

αTIGIT-guided IL-15 mimetics drive potent and safe antitumor immunity by restoring tumor-infiltrating T cells

This study highlights a strategy to use TIL-targeted cytokine mimetics to overcome the limitations of native cytokines and enable dose pairing with immune checkpoint blockade (ICB), offering a path toward safer and more effective cytokine immunotherapy.

Xiang-Ming Liu, Nan Li, Yu-Meng Chen et al. · 0 citations
Open access Sep 2026

Combination Of Bispecific Antibodies Enable Targeted TNFRSF Agonism and Effective Antitumor Activity.

4-1BB is an inducible costimulatory molecule that requires receptor clustering to boost anti-cancer immune response. However, the clinical development of monoclonal antibodies targeting 4-1BB has been constrained by toxicities driven by systemic activation. To address this, bispecific antibodies (bsAbs) have been devel...

Lucie Diby, P. Malinge, V. Moine et al. · 0 citations
Review Open access Sep 2026

CD97/ADGRE5 in Cancer: Structural Activation, Context-Dependent Signaling, and Therapeutic Targeting

CD97 is an adhesion G-protein-coupled receptor encoded by ADGRE5 that integrates extracellular signals (including cell adhesion, ligand binding, and mechanical stimulation) with intracellular signal transduction and is involved in tumor stemness, invasion, metastasis, and cell survival through adhesion-related signalin...

Yu-Hong Lei, Yuan Zhang, Yu-Feng Wang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.